The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation.

Seiichiro MitaniHiroya TaniguchiKeiji SugiyamaToshiki MasuishiKazunori HondaYukiya NaritaShigenori KadowakiTakashi UraMasashi AndoMasahiro TajikaYasushi YatabeKei Muro

Published in: Therapeutic advances in medical oncology (2019)

Outcomes of second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation were extremely poor. GPS may be useful in future clinical trials.

Keyphrases

metastatic colorectal cancer
clinical trial
locally advanced
current status
squamous cell carcinoma
chemotherapy induced
rectal cancer
type diabetes
phase ii
metabolic syndrome
skeletal muscle
open label
weight loss